09 / 08 / 2022
Save the date for our new in vivo shuttle campaign!
We are committed to providing world-class supports to advance your preclinical projects and immunotherapy drug discovery using syngeneic tumor mouse models through our comprehensive in vivo Immuno-Oncology platform.
Sign up! It’s for early November
07 / 12 / 2022
Check out - it's our favorite image of the month
What a pretty multiplexed image showing the tumor microenvironment (TME) on a human NSCLC section, highlighting PDL1 positive tumor cells surrounded by macrophages and T cells.
07 / 07 / 2022
Discover our main news for the first half of 2022!
Hear about the great opportunity that is our partnership with Domain Therapeutics, new cutting-edge platforms for biomarker translational research as well as our newest featured publication!
06 / 16 / 2022
Check out - it's our favorite image of the month
Summer beginning, look at a real fireworks 🎆! Human cerebral cortex nerve cells lit up on section!
05 / 19 / 2022
From June 3 to 7, 2022, we will be setting up our quarters in Chicago for the American Society of Clinical Oncology Annual Meeting to continue gaining the latest insights in research and clinical development in Oncology. Also, our CEO Dr. Alban Bessede will have the great opportunity to present a scientific poster highlighting our recent advances in biomarker research in Immuno-Oncology.
05 / 04 / 2022
In the era of immuno-oncology, it’s critical to unravel mechanisms of action underlying sensitivity or resistance to current immunotherapies in order to identify predictive biomarkers of response and then discover novel actionable therapeutic targets.
04 / 21 / 2022
Back from the AACR 2022, it was a pleasure to take part in it and to converse about our posters showcasing our newest preclinical and translational research advances in Immuno-Oncology.
If you didn't get the chance to meet us and see our posters, or if you want to review them, you can directly download them from the form below.
03 / 29 / 2022
We will be attending the AACR Annual Meeting in New Orleans, from April 8 to 13, 2022. We will be glad to take this opportunity to meet you there, approach your research projects and introduce our service offerings. We will also presentsome scientific posters to highlight our latest innovative preclinical and translational research advances.
03 / 10 / 2022
Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), and Explicyte, an expert in the field of IO and innovative target identification through multiparametric approaches, announce today the signing of a partnership agreement. The two companies will combine their expertise to identify GPCR targets and associated biomarkers to discover and develop breakthrough therapeutic programs for IO. Financial terms are not disclosed.
01 / 27 / 2022
January 27, 2022 – The CONDOR consortium, led by Pr. Antoine Italiano of the Bergonié Institute (Bordeaux, France) is one of the 17 national awardees in the fifth call for projects in Hospital-University Research in Health (RHU5), selected from the 89 applications submitted. This €30M ($34M) project will benefit from a grant of more than €9.8M ($11.1M) to implement a multi-modal project combining precision medicine and immunotherapies for the management of patients with Soft Tissue Sarcomas (STS).